The Salford Lung Study is a way to improve asthma control in real clinical practice (a review)
https://doi.org/10.18093/0869-0189-2017-27-5-672-678
Abstract
The Salford Lung Study in asthma (SLS-Asthma) is the first prospective, randomized, controlled clinical trial conducted in conditions and in population that were very close to real clinical practice. The study demonstrated that treatment of a large heterogeneous population of asthma patients using combination of vilanterol (VI) and fluticasone furoate (FF) (22/92 mg q.d. or 22/184 mg q.d.) via Ellipta dry powder inhaler provided better control of the disease than the conventional therapy administered by an attendant physician. The level of asthma control in VI/FF group was consistently maintained for 12 months with no identified change in risk of development of serious adverse events. Results were similar in patients receiving ICS or ICS/LABA combinations and did not depend on smoking status or number of exacerbations over the previous year.
About the Authors
V. N. Vargina
CJC GlaxoSmithKline Traiding
Russian Federation
Russian Federation
Candidate of Medicine, Medical Affairs Manager, Respiratory Portfolio
tel.: 495-777-89-00
ul. Krylatskaya 17, build. 3, Moscow, 121614, Russia
E. N. Barabanova
CJC GlaxoSmithKline Traiding
Russian Federation
Russian Federation
Candidate of Medicine, Medical & Scientific Communications Manager
tel.: 495-777-89-00
ul. Krylatskaya 17, build. 3, Moscow, 121614, Russia
References
1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2017. Available at: www.ginasthma.com [Accessed 03 October, 2017].
2. Hannan E.L. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc. Interv. 2008; 1 (3): 211–217. DOI: 10.1016/j.jcin.2008.01.008.
3. Herland K., Akselsen J.P., Skjønsberg O.H., Bjermer L. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir. Med. 2005; 99 (1): 11–19. DOI: 10.1016/j.rmed.2004.03.026.
4. Agusti A.A., de Teresa L., De Backer W. et al. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. J. Eur. Respir. 2014; 43 (3): 763–772. DOI: 10.1183/09031936.00054213.
5. Tamura G., Ohta K. Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir. Med. 2007; 101 (9): 1895–1902. DOI: 10.1016/j.rmed.2007.05.001.
6. Berger M.L., Dreyer N., Anderson F. et al. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. Value Health. 2012; 15 (2): 217–230. DOI: 10.1016/j.jval.2011.12.010.
7. Woodcock A., Vestbo J., Bakerly N.D. et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Lancet. 2017; Published online September 10, 2017. DOI: 10.1016/S0140-6736(17)32397-8.
8. Thomas M., Kay S., Pike J. et al. The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim. Care Respir. J. 2009; 18 (1): 41–49. DOI: 10.4104/pcrj.2009.00010.
9. Schatz M., Sorkness C.A., Li J.T. et al. Asthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J. Allergy Clin. Immunol. 2006; 117 (3): 549–556.
10. Ko F.W., Hui D.S., Leung T.F. et al. Evaluation of the asthma control test: a reliable determinant of disease stability and a predictor of future exacerbations. Respirology. 2012; 17: 370–378. DOI: 10.1111/j.1440-1843.2011.02105.x.
11. Soler X., Holbrook J.T., Gerald L.B. et al. Validity of the Asthma Control Test Questionnaire among Smoking Asthmatics. J. Allergy Clin. Immunol. Pract. 2017 [Epub. ahead of print].
12. de Araujo G.V., Leite D.F., Rizzo J.A., Sarinho E.S. Asthma in pregnancy: association between the Asthma Control Test and the Global Initiative for Asthma classification and comparisons with spirometry. Eur. J. Obstet. Gynecol. Reprod. Biol. 2016; 203: 25–29.
13. Schatz M., Mosen D.M., Kosinki M. et al. Validity of the Asthma Control Test completed at home. Am. J. Manag. Carе. 2007; 13 (12): 661–667.
14. Peters S.P., Jones C.A., Haselkorn T. et al. Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national web-based survey. J. Allergy Clin. Immunol. 2007; 119: 1454–1461.
15. Schatz M., Mosen D.M. Reliability and predictive validity of the Asthma Control Test administered by telephone calls using speech recognition technology. J. Allergy Clin. Immunol. 2007; 119: 336–343.
16. Gibson P. Effectiveness trials in asthma: time to SaLSA? Lancet. 2017. Published online September 10, 2017.
Review
For citations:
Vargina V.N., Barabanova E.N. The Salford Lung Study is a way to improve asthma control in real clinical practice (a review). PULMONOLOGIYA. 2017;27(5):672-678. (In Russ.) https://doi.org/10.18093/0869-0189-2017-27-5-672-678
Views:
850
Email this article 